Methamphetamine use disorder.
Conditions
Interventions
Intervention 1: Intervention group:The intervention group will receive 1200 mg NAC daily in two divided doses for 12 weeks, and the placebo group will receive a placebo similar in size and shape in th
Sponsors
University of social welfare and rehabilitation sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 18 to 65 years Diagnosis of methamphetamine use disorder (MUD), based on DSM-5-TR Absence of acute or chronic physical disorders such as acute infection, cardiovascular, hepatic, or renal diseases in the past three months Absence of psychiatric disorders or history of suicide at least one month prior to study entry and no use of antidepressant medications in the past month (substance-induced psychotic and mood disorders are excluded) No current dependence on cocaine, alcohol, or benzodiazepines and no dependence on alcohol during the three years prior to study initiation Completion of the informed consent form for entry into the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the substance craving score based on the Substance Craving Assessment Questionnaire. Timepoint: The substance craving test will be performed at baseline (before the start of the intervention) and at 4, 8, and 12 weeks after the start of the intervention. Method of measurement: Substance Craving Assessment Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of urine samples negative for methamphetamine and reduction in substance use based on urine test results. Timepoint: Before the start of the intervention and at weeks 4, 8, and 12 after the start of the intervention. Method of measurement: Urine sample.;Number of weeks of complete abstinence and treatment success rate. Timepoint: At baseline and at weeks 4, 8, and 12. Method of measurement: Treatment success will be defined as abstinence from methamphetamine for 21 days or self-reported reduction of methamphetamine use by more than 50% compared with baseline use. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShokouh Gheibi
University of social welfare and rehabilitation sciences
Outcome results
None listed